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Abstract
A 14 year old female with type 1 diabetes mellitus and a subcutaneous insulin pump was treated for
diabetic ketoacidosis presumed secondary to dietary indiscretion, and then restarted her
subcutaneous insulin pump after exchanging the tubing. An hour later, nursing review determined
that she was using outdated insulin in the pump, and it was exchanged. However, 5 hours later
relapse was suggested by a rise in capillary blood 3-hydroxybutyrate, in spite of a normal serum anion
gap and a minimal increase in serum bicarbonate. Insulin pump failure was suspected, and the patient
was treated for relapse of diabetic ketoacidosis. Following resolution, her insulin pump was replaced
without further complications. Capillary blood levels of 3-hydroxybutyrate may be sensitive, early
indicators of relapse of diabetic ketoacidosis, and are easily obtained.
Introduction
A capillary blood assay for 3-hydroxybutyrate (BHB) has
been used at home [1], in hospital emergency departments
[2,3] and during hospitalization [4-7] to diagnose and
help manage patients with diabetic ketoacidosis (DKA).
Capillary blood BHB tests have been used to document the
persistence of ketones even while the urine nitroprusside
test for ketones showed their clearance during therapy for
DKA [8], and one might predict that these capillary blood
BHB tests would have utility in detecting relapse following
therapy for DKA. Nevertheless, capillary blood BHB testing
is not yet routinely available in all children’s hospitals.
An adolescent with a subcutaneous insulin pump and
DKA is reported with an early relapse due to insulin pump
malfunction, diagnosed by an increase in capillary blood
BHB prior to any increase in the anion gap or decline in
serum bicarbonate. This case provides further support for
the need to monitor capillary blood BHB during therapy
for pediatric DKA.
Case presentation
A 14 year old Caucasian female (United States citizen) with
type 1 diabetes mellitus and therapy with a subcutaneous
insulin pump for a year, was admitted with severe [9] DKA
(arterial blood gas pH 6.96), with serum glucose: 816 mg/
dL,PaCO2:17mmHg,serumaniongap:38,and3+ketones
on serum nitroprusside test. She noted dietary indiscretion.
Additional laboratory data on admission included serum
sodium 120 mmol/L, potassium 5.1 mmol/L, chloride
78 mmol/L, bicarbonate <5 mmol/L, blood urea nitrogen
40 mg/dL, creatinine 1.2 mg/dL, and calcium 10.2 mg/dL.
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(University Hospital, University of Medicine and Dentistry
of New Jersey in Newark, New Jersey), hourly testing of
capillary blood BHB (using the Precision Xtra System for
BHB; Abbott Laboratories, MediSense Products Inc; Bed-
ford, MA) was performed concurrently with glucose (finger-
stick) testing (Figure 1). Her insulin pump was
discontinued, and she received a continuous infusion of
intravenous insulin (0.1 to 0.14 units/kg/hr) and rehydra-
tion. The serum anion gap and capillary blood BHB fell to
normal levels (<12 and <0.5 mmol/L, respectively) at 14
hours. Due to persistent metabolic acidosis, the insulin
infusion was continued for a total of 42 hours, when serum
[bicarbonate] was 18 mmol/L. She felt much better and
resumedherregulardietandtherapywithhersubcutaneous
insulin pump (after changing all pump tubing).
Serum bicarbonate fell to 15 mmol/L while serum
chloride increased to 116 mmol/L (serum anion gap: 9)
less than 1 hour later. Subsequently, she had a meal as well
as a snack. Within an hour of restarting the insulin pump,
nursing staff determined that the patient had been using
outdated insulin, and this was rectified. She was given
several extra doses of subcutaneous (regular) insulin over
the next 4 hours. Five hours after discontinuation of the
intravenous insulin infusion, serum bicarbonate rose
slightly to 16 mmol/L and the anion gap was 9, though
hyperglycemia recurred (serum glucose: 501 mg/dL).
Simultaneously, capillary blood BHB rose to 1.1 mmol/L.
The insulin pump was again stopped and the patient
received 20 more hours of intravenous insulin infusion
and hydration; her serum bicarbonate was then 24 mmol/
L with euglycemia. The pump was then replaced due to a
malfunction, and the patient was discharged home with-
out further complications.
Discussion
An episode of DKA in a patient with a subcutaneous
insulin pump mandates a detailed review to discover the
cause: in this patient, a dietary indiscretion was initially
suspected, though outdated insulin was subsequently
noted and exchanged. However, mechanical pump failure
complicated this case, and was responsible for relapse
shortly following resumption of a normal diet.
At the time relapse was diagnosed, the serum bicarbonate
had increased slightly with concurrent hyperchloremic
metabolic acidosis and postprandial hyperglycemia.
Hyperchloremic metabolic acidosis may be associated
with DKA, either on presentation or as a result of therapy
[10], as in this patient. Nevertheless, the capillary blood
BHB was also tested and confirmed relapse of DKA [11]
secondary to subcutaneous insulin pump malfunction.
Progressive ketosis can develop soon after interruption of a
continuous insulin infusion in diabetics [12]. It is likely
that recognition of DKA relapse in this patient would have
been delayed in the absence of capillary blood BHB
testing.
Interest and experience with subcutaneous insulin
pump therapy is increasing [13], and practical experi-
ence with the management of these patients while
hospitalized may be helpful. Multiple triggers for DKA
may be present in diabetic children treated with a
subcutaneous insulin pump, as in this patient. Capillary
blood BHB is helpful in detecting relapse: a fingerstick
BHB level is easily obtained at the bedside in conjunc-
tion with a glucose level and does not entail significant
delays in processing. Capillary blood BHB levels have
been recommended as routine for managing sick
children with diabetes [1], and this technology “is a
useful adjunct to laboratory-based determinations”
according to a consensus statement from the American
Diabetes Association [9]. It may be particularly useful
for monitoring sick children with diabetes and a
subcutaneous insulin pump [14].
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Figure 1. Serum [bicarbonate] and anion gap (AG) with
capillary blood [BHB] in patient with DKA and subcutaneous
insulin pump.
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